What is preemption, and what does it mean for drug lawsuits?

The Supreme Court considers whether patients hurt by drugs can sue drug companies that followed U.S. Food and Drug Administration guidelines















Share on Tumblr



SHEILA SCHEUERMAN Image: courtesy Sheila Scheuerman

In the spring of 2000 a professional guitarist named Diana Levine, then in her 50s, sought treatment for a migraine headache at a clinic in Vermont. She usually received the drug Demerol for pain relief, along with an injection of Wyeth’s antinausea drug Phenergan in the muscles of her butt to relieve the nausea that usually accompanies migraines. But this time the physician’s assistant used an alternative method for administering Phenergan approved by the U.S. Food and Drug Administration. In the method, called intravenous push, the drug is injected directly into a vein in the arm.

The physician’s assistant, however, missed Levine’s vein and accidentally injected Phenergan into her artery. Over the next few weeks, Levine experienced excruciating pain. Her hand and forearm turned black with infection, and both had to be amputated later.

Levine sued Wyeth for failing to warn her about the gangrene risk associated with IV push, and a Vermont jury ordered the drugmaker pay $6.7 million in damages. But Wyeth had, in fact, disclosed the risk of intra-arterial injection on their FDA-approved label, so they appealed. The Vermont Supreme Court upheld the lower court’s ruling in 2006. This week, the Supreme Court is hearing arguments on the case.

Suddenly, everyone within earshot of a trial lawyer is talking about "preemption," which is the legal issue at stake in the case. It's already generated a lot of coverage and buzz, and is being watched closely by lawyers and advocates who say it could dramatically change the drug lawsuit landscape. Similar cases are working their ways through other courts, including one in New Jersey involving Merck and Vioxx. You'll recall that people who took Vioxx—a painkiller now off the market—are suing Merck because studies later showed that it doubled the risk of heart attacks. Some are even speculating about what a new president and Congress will be able to do about the eventual ruling.

We asked Sheila Scheuerman, a professor at the Charleston School of Law and an expert in tort law and product liability, to explain preemption and what the case means for lawsuits. An edited transcript of the interview follows.

What does preemption mean?
Preemption refers to a defense when you are in a Federal Court where federal law supplants state law. There are two kinds of preemption.  Expressed preemption is where Congress expressly says no state law in contradiction to or related to an area is allowed. Implied preemption is where there is no expressed preemption provision but allowing state law would conflict with the purposes of a federal statute, such as the Food, Drug and Cosmetic Act that authorizes the FDA to approve the release of new drugs into the market.

How does implied preemption apply to Wyeth v. Levine?
Levine sued for negligence under Vermont state law. Her allegation was that Wyeth had failed to provide proper instruction regarding this IV push method.  It shouldn’t be administered that way, she alleges, and instead should use the IV drip method.

The argument that Wyeth is making here is it had to submit its labeling to the Food and Drug Administration for approval and that holding Wyeth liable under Vermont law conflicts with the approval process. Allowing Levine’s claim conflicts with the IV push method that the Food and Drug Administration has approved. It’s really a fascinating case in terms of the policy on both sides.



2 Comments

Add Comment
View
  1. 1. bucketofsquid 11:52 AM 11/6/08

    Not being a lawyer I'm a little confused. The pharma company didn't miss the vein and hit the artery. That was the person that gave the treatment. If they had administered the treatment correctly there would have been no injury. How is this the pharma companys fault? The liability should fall on the facility and its staff.

    Reply | Report Abuse | Link to this
  2. 2. Jaynesday 09:13 AM 11/9/08

    To learn more about Preemption go to the site
    - http://pharmaccountability.org See what
    organizations listed below have to say about
    the current state of drug and device safety in
    the United States along with the adverse effect
    that preemption will have on our safety and
    civil rights.
    1. The Journal of American Medical Association
    2. The New England Journal of Medicine
    3. The FDA itself
    4. The New York Times
    5. The Boston Globe
    6. The United States House of Representatives
    Committee on Oversight and Reform
    7. Past Commissioner of the FDA - David A.
    Kessler, M.D
    8. 47 State Attorneys Generals
    9. Senior Citizens League
    10. AARP
    11. National Conference of State Legislatures.
    12. California Medical Association
    13. Various others
    See what Preemption is all about and see what
    you can do about it by contacting your Congress
    person today.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital

Latest from SA Blog Network

  SA Digital

Science Jobs of the Week

Email this Article

What is preemption, and what does it mean for drug lawsuits?

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X